| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HSCS | Employee Stock Option (Right to Buy) | Award | +9,000 | 9,000 | 16 Jan 2025 | Common Stock | 9,000 | $3.33 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. |
| F2 | One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of April 16, 2026 (the "Subsequent Vesting Date") and thereafter on each successive three-month anniversary of the Subsequent Vesting Date for the next seven fiscal quarters, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration. As of the date of this filing, such regulatory clearance has not been received. |
| F3 | These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement. |
Chief Financial Officer and Treasurer